1. Home
  2. TLSI vs BDMD Comparison

TLSI vs BDMD Comparison

Compare TLSI & BDMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TLSI
  • BDMD
  • Stock Information
  • Founded
  • TLSI 2010
  • BDMD 2012
  • Country
  • TLSI United States
  • BDMD China
  • Employees
  • TLSI N/A
  • BDMD N/A
  • Industry
  • TLSI Medical Specialities
  • BDMD
  • Sector
  • TLSI Health Care
  • BDMD
  • Exchange
  • TLSI Nasdaq
  • BDMD NYSE
  • Market Cap
  • TLSI 160.4M
  • BDMD 196.9M
  • IPO Year
  • TLSI N/A
  • BDMD N/A
  • Fundamental
  • Price
  • TLSI $5.19
  • BDMD $5.17
  • Analyst Decision
  • TLSI Strong Buy
  • BDMD
  • Analyst Count
  • TLSI 6
  • BDMD 0
  • Target Price
  • TLSI $11.75
  • BDMD N/A
  • AVG Volume (30 Days)
  • TLSI 34.3K
  • BDMD 35.0K
  • Earning Date
  • TLSI 05-14-2025
  • BDMD 01-01-0001
  • Dividend Yield
  • TLSI N/A
  • BDMD N/A
  • EPS Growth
  • TLSI N/A
  • BDMD 4212.17
  • EPS
  • TLSI N/A
  • BDMD 0.43
  • Revenue
  • TLSI $29,431,000.00
  • BDMD $33,048,249.00
  • Revenue This Year
  • TLSI $56.00
  • BDMD N/A
  • Revenue Next Year
  • TLSI $52.17
  • BDMD N/A
  • P/E Ratio
  • TLSI N/A
  • BDMD $12.54
  • Revenue Growth
  • TLSI 58.99
  • BDMD 11.28
  • 52 Week Low
  • TLSI $3.50
  • BDMD $1.05
  • 52 Week High
  • TLSI $10.24
  • BDMD $13.52
  • Technical
  • Relative Strength Index (RSI)
  • TLSI 40.35
  • BDMD N/A
  • Support Level
  • TLSI $4.66
  • BDMD N/A
  • Resistance Level
  • TLSI $5.35
  • BDMD N/A
  • Average True Range (ATR)
  • TLSI 0.37
  • BDMD 0.00
  • MACD
  • TLSI -0.05
  • BDMD 0.00
  • Stochastic Oscillator
  • TLSI 43.44
  • BDMD 0.00

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

About BDMD BAIRD MEDICAL INVESTMENT HLDGS LTD

Baird Medical Investment Holdings Ltd is one of the microwave ablation medical device developers and providers in the PRC for minimally invasive treatment of tumors. Its proprietary medical devices are used for the treatment of benign and malignant tumors, including thyroid nodules, liver cancer, lung cancer and breast lumps. Microwave ablation is a minimally invasive treatment technique that denaturalizes and coagulates the protein of tumor cells with extreme heat generated by microwave energy. Microwave ablation treatments have been applied to benign and malignant tumors, and the company believes the products are safer, minimally invasive and easier to operate with faster recovery periods and lower complication rates for patients, as compared to traditional treatment methods.

Share on Social Networks: